TSP Therapeutics is a technology company.
TSP Therapeutics has raised $30K across 1 funding round.
TSP Therapeutics has raised $30K in total across 1 funding round.
TSP Therapeutics has raised $30K in total across 1 funding round.
TSP Therapeutics's investors include Health Wildcatters, John Parker.
TSP Therapeutics is a biopharmaceutical company developing histamine signaling therapies, specifically reformulating histamine 2 receptor agonists, to overcome acquired resistance to cancer immunotherapies like aldesleukin or PD-1/PD-L1 inhibitors.[2][5] These therapies reduce immunosuppressive cells and enhance antitumor immune responses in the tumor microenvironment, targeting cancers such as acute myeloid leukemia (AML) remission maintenance and potentially others.[2] The company serves cancer patients by improving immunotherapy outcomes through repurposed drugs, with recent momentum from a strategic partnership with Fitabeo Therapeutics to enable oral thin-film delivery, replacing cumbersome subcutaneous administration and facilitating expansion via faster regulatory pathways.[2]
TSP Therapeutics was co-founded by Al Paz, MBA, who serves as Founder, President, and CEO with nearly 40 years in bio/pharmaceuticals across oncology and other areas, and Jeffrey C. Miller, MBA, a co-founder and partner at KASTx Ventures with over 25 years in the industry spanning rare diseases and oncology.[4] Xiuling Lu, PhD, acts as CSO and co-founder, bringing over 18 years in drug formulation, nanotechnologies for cancer therapy, multiple patents, and academic leadership at the University of Connecticut.[4] The idea emerged from expertise in addressing immunotherapy resistance via histamine agonists, building on leaders' extensive oncology experience; early traction includes drug pipelines, patents, clinical trials, and the Fitabeo partnership for innovative delivery in AML and beyond.[1][2][4]
TSP Therapeutics rides the immunotherapy resistance wave in oncology, where acquired resistance limits PD-1/PD-L1 and IL-2 therapies' efficacy, a market force amplified by rising cancer incidence and demand for combination regimens.[2][5] Timing aligns with advances in drug repurposing and novel delivery like thin-films, enabling decentralized care and broader adoption amid regulatory shifts favoring hybrid pathways.[2] It influences the ecosystem by partnering with platform innovators (e.g., Fitabeo) and leveraging networks from leaders' Big Pharma ties (e.g., GSK), accelerating oncology pipelines and supporting talent expansion in drug development.[2][3][4]
TSP Therapeutics is poised to advance its histamine agonist pipeline into clinical expansion beyond AML, driven by the Fitabeo partnership's oral delivery unlocking peptide/protein applications and multi-cancer potential.[2] Trends like AI-aided formulation, combo immunotherapy dominance, and patient-centric dosing will shape growth, with the team's deep oncology expertise enabling partnerships and IND progress.[4] Influence may evolve from niche resistance-solver to key player in next-gen immuno-oncology, enhancing patient outcomes where current therapies fall short—reinforcing its mission to reformulate for better tumor microenvironments.[2][5]
TSP Therapeutics has raised $30K across 1 funding round. Most recently, it raised $30K Seed in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $30K Seed | Health Wildcatters, John Parker |